EVALUATION OF THE ABСВ1 GENE POLYMORPHISMS EFFECTS ON THE АPIXABAN’S PHARMACOKINETIC PARAMETERS IN THE KAZAKH POPULATION
Introduction. Atrial fibrillation is a heart rhythm disorder. Apixaban is a direct-acting anticoagulant whose mechanism of action is to inhibit the activity of clotting factor Xa. The literature shows that polymorphisms of the ABCB1 gene are the most common genetic variants that contribute to the change in peak and trough levels of drugs with a proven clinical effect.
Purpose of the study. Study of the effect of ABCB1 gene polymorphisms on apixaban concentrations in patients with atrial fibrillation in the Kazakh population.
Methods. Genomic DNA was isolated from peripheral blood samples using a commercial Thermo Scientific GeneJET Whole Blood Genomic DNA Purification Mini Kit (Thermo Fisher Scientific) according to the manufacturer's instructions. DNA concentration was measured on a Nanodrop 1000 spectrophotometer. SNP genotyping was performed using TaqMan technology.
Results. In this study, no statistically significant differences were found in peak or minimum concentrations of apixaban in blood plasma with different genotypes of ABCB1 gene polymorphisms (rs4148738, rs1045642, rs2032582, rs1128503) in the Kazakh population.
Conclusions: Analysis of the influence of genetic factors on the activity of enzymes involved in the metabolism of the drug will help expand the possibilities of personalized medicine for individualizing treatment. It is necessary to conduct more extensive studies to study the effect of the carriage of ABCB1 polymorphisms on the metabolism of apixaban in various ethnic populations.
Ayan Abdrakhmanov1,2, https://orcid.org/0000-0001-6315-5016
Elena Zholdybaeva3, https://orcid.org/0000-0002-9677-00
Aizhan Shaimerdinova4, https://orcid.org/0000-0001-9479-8006
Yelena Rib4, https://orcid.org/0000-0001-6265-8121
Svetlana Abildinova1, Gulnara Tuyakova1, Zhanasyl Suleimen1,
Makhabbat Bekbosynova1, https://orcid.org/0000-0003-2834-617X
1 NJSC "National Scientific Cardiosurgical Center", Astana c., Republic of Kazakhstan;
2 Hospital of the Medical Center of the Office of the President, Astana c., Republic of Kazakhstan;
3 National Biotechnology Center of the Ministry of Health of the Republic of Kazakhstan, Astana c., Republic of Kazakhstan;
4 Astana Medical University, Astana c., Republic of Kazakhstan.
1. Alalwan A.A., Voils S.A., Hartzema A.G. Trends in utilization of warfarin and direct oral anticoagulants in older adult patients with atrial fibrillation // Am. J. Health-Syst. Pharm. Ajhp Off. J. Am. Soc. Health-Syst. Pharm. 2017. 74. 1237–1244.
2. Cherubini A., Carrieri B., Marinelli P. Advantages and disadvantages of direct oral anticoagulants in older patients // Geriatr. Care. 2018. 4. 7227.
3. Kanuri S.H., Kreutz R.P. Pharmacogenomics of Novel Direct Oral Anticoagulants: Newly Identified Genes and Genetic Variants // J Pers Med. 2019 Jan 17.-9(1):7. -doi: 10.3390/jpm9010007. PMID: 30658513; PMCID: PMC6463033. https://pubmed.ncbi.nlm.nih.gov/30658513/ (Дата обращения: 23.12.2022)
4. Satybaldyeva M.A., Reshetnyak T.M. New oral anticoagulants in the therapy of antiphospholipid syndrome // Rheumatology Science and Practice. 2016-54(2):219-226. (rus)
5. Benilde Cosmi, Luisa Salomone, Michela Cini, Giuliana Guazzaloca and Cristina Legnani. Observational Study of the Inter-Individual Variability of the Plasma Concentrations of Direct Oral Anticoagulants (Dabigatran, Rivaroxaban, Apixaban) and the Effect of rs4148738 Polymorphism of ABCB1 // Journal of Cardiology and Therapeutics, 2019. 7. 8-14. https://api.semanticscholar.org/CorpusID:213685940 (Дата обращения: 29.11.2022)
6. Dimatteo C., D'Andrea G., Vecchione G. et al. Pharmacogenetics of dabigatran etexilate interindividual variability // Thromb Res. Aug 2016. 144:1-5. https://doi.org/10.1016/j.thromres.2016.05.025 (Дата обращения: 18.01.2023)
7. Raghavan N., Frost C.E., Yu Z., He K., Zhang H., Humphreys W.G., Pinto D., Chen S., Bonacorsi S., Wong P.C. et al. Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans // Drug Metab. Dispos. 2009, 37. 74–81.
8. Frost C.E., Song Y., Shenker A., Wang J., Barrett Y.C., Schuster A., Harris S.I., LaCreta F. Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban // Clin Pharmacokinet. 2015 Jun.54(6):651-62. doi: 10.1007/s40262-014-0228-0. PMID: 25573421. PMCID: PMC4449375. https://pubmed.ncbi.nlm.nih.gov/25573421/ (Дата обращения: 18.01.2023)
9. Kaufman A.L., Spitz J., Jacobs M., Sorrentino M., Yuen S., Danahey K., Saner D., Klein T.E., Altman R.B., Ratain M.J., O'Donnell P.H. Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs // Mayo Clin Proc. 2015 Jun. 90(6):716-29. doi: 10.1016/j.mayocp.2015.03.016.-PMID: 26046407. -PMCID: PMC4475352. https://pubmed.ncbi.nlm.nih.gov/26046407/ (Дата обращения: 19.01.2023)
10. Kampouraki E., Kamali F. Pharmacogenetics of anticoagulants used for stroke prevention in patients with atrial fibrillation // Expert Opinion on Drug Metabolism & Toxicology, 2019 Jun. 15(6):449-458. -DOI:10.1080/17425255.2019.1623878. https://pubmed.ncbi.nlm.nih.gov/31120800/ (Дата обращения: 23.12.2022)
11. Raymond J., Imbert L., Cousin T., Duflot T., Varin R., Wils J., Lamoureux F. Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review // J Pers Med. 2021 Jan 11.11(1). 37. doi: 10.3390/jpm11010037. PMID: 33440670. PMCID: PMC7826504. https://pubmed.ncbi.nlm.nih.gov/33440670/ (Дата обращения: 25.01.2023)
12. Adela-Nicoleta Rosian, Mihaela Iancu, Adrian Pavel Trifa, Stefan Horia Ro¸sian, Cristina Mada, Cornelia Paula Gocan, Teodora Nita, Sabina Istratoaie , Paul-Mihai Boarescu. Anca Dana Buzoianu. An Exploratory Association Analysis of ABCB1 rs1045642 and ABCB1 rs4148738 with Non-Major Bleeding Risk in Atrial Fibrillation Patients Treated with Dabigatran or Apixaban // Journal of Personalized Medicine. 2020. 10.133. doi:10.3390/jpm10030133 https://pubmed.ncbi.nlm.nih.gov/32961964/ (Дата обращения: 29.11.2022)
13. Dimatteo C., D'Andrea G., Vecchione G., Paoletti O., Tiscia G.L., Santacroce R., Correale M., Brunetti N., Grandone E., Testa S., Margaglione M. ABCB1 SNP rs4148738 modulation of apixaban interindividual variability // Thromb Res. 2016 Sep. 145: 24-6. doi: 10.1016/j.thromres.2016.07.005. Epub 2016 Jul 12. PMID: 27434880. https://pubmed.ncbi.nlm.nih.gov/27434880/ (Дата обращения: 23.12.2022)
14. Ueshima S., Hira D., Kimura Y., Fujii R., Tomitsuka C., Yamane T., Tabuchi Y., Ozawa T., Itoh H., Ohno S., Horie M., Terada T., Katsura T. Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation // Br J Clin Pharmacol. 2018 Jun. 84(6):1301-1312. doi: 10.1111/bcp.13561. Epub 2018 Apr 16. PMID: 29457840. -PMCID: PMC5980466. https://pubmed.ncbi.nlm.nih.gov/29457840/ (Дата обращения: 29.11.2022)
15. Roşian A., Roşian Ş., Kiss B, Ştefan M., Trifa A., Ober C., Anchidin O, Buzoianu A. Interindividual Variability of Apixaban Plasma Concentrations: Influence of Clinical and Genetic Factors in a Real-Life Cohort of Atrial Fibrillation Patients // Genes (Basel). 2020 Apr 17. -11(4):438. doi: 10.3390/genes11040438. https://pubmed.ncbi.nlm.nih.gov/32316515 (Дата обращения: 25.01.2023)
16. Attelind S., Hallberg P., Wadelius M., Hamberg A., Siegbahn A., Granger C., Lopes R.D., Alexander J.H., Wallentin L., Eriksson N. Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events // Front. Genet. 2022. 13:982955. doi:10.3389/fgene.2022.982955 https://pubmed.ncbi.nlm.nih.gov/36186466/ (Дата обращения: 19.01.2023)
17. Kryukov A.V., Sychev D.A., Andreev D.A., Ryzhikova K.A., Grishina E.A., Ryabova A.V., Loskutnikov M.A., Smirnov V.V., Konova O.D., Matsneva I.A., Bochkov P.O. Influence of ABCB1 and CYP3A5 gene polymorphisms on pharmacokinetics of apixaban in patients with atrial fibrillation and acute stroke. // Pharmgenomics Pers Med. 2018. Vol 22, №11. P.43-49. doi: 10.2147/PGPM.S157111.
18. Lähteenmäki J., Vuorinen A.L., Pajula J., Harno K., Lehto M., Niemi M., van Gils M. Pharmacogenetics of Bleeding and Thromboembolic Events in Direct Oral Anticoagulant Users // Clin Pharmacol Ther. 2021. Vol.110, №3. P.768-776. doi: 10.1002/cpt.2316.
19. Gulilat M., Keller D., Linton B., Pananos A.D., Lizotte D., Dresser G.K., Alfonsi J., Tirona R.G., Kim R.B., Schwarz U.I. Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care // J Thromb Thrombolysis. 2020 Feb. 49(2):294-303. doi: 10.1007/s11239-019-01962-2
Number of Views: 203
Category of articles:
Original articles
Bibliography link
Abdrakhmanov A. Zholdybaeva Ye., Shaimerdinova A., Rib Ye., Abildinova C., Tuyakova G., Suleimen Zh., Bekbosynova M. Evaluation of the ABСВ1 gene polymorphisms effects on the Apixaban’s pharmacokinetic parameters in the Kazakh population // Nauka i Zdravookhranenie [Science & Healthcare]. 2023, (Vol.25) 3, pp. 32-39. doi 10.34689/SH.2023.25.3.004Related publications:
ANALYSIS OF CLINICAL AND DEMOGRAPHIC INDICATORS OF PATIENTS WITH PARKINSON'S DISEASE IN THE SOUTHERN REGION OF KAZAKHSTAN
A COMPARATIVE STUDY OF DRUG POLICY REGARDING ORPHAN DISEASES IN THE USA, THE EUROPEAN UNION, AND THE REPUBLIC OF KAZAKHSTAN
MUTATIONS IN CARDIAC ION CHANNEL GENES IN KAZAKHSTANI PATIENTS WITH LONG QT SYNDROME
GENETIC FEATURES OF CONGENITAL DYSFUNCTION OF THE ADRENAL CORTEX CAUSED BY 21-HYDROXYLASE DEFICIENCY IN PERSONS OF KAZAKH NATIONALITY
NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE USING THE EXAMPLE OF AKTOBE PATIENTS